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Introduction 
Heavy metals are one of the most important environmental 
pollutants whose rate of entry into water resources is increas-
ing through agricultural, industrial and urban development 
activities [1-3]. Among heavy metals the inorganic arsenic 
(iAs) is a carcinogen that ranks the 20th in terms of frequency 
of elements in the earth’s crust with an average of 1.8 mg/kg. It 
is naturally found in the oxidation state of AsV (arsenate) and 
AsIII (arsenite), the latter being about 60 times more toxic than 
the former [4].
The biotransformation pathway of As involves several chang-
es in oxidative state, oxidative methylation, and production of 
at least four metabolites. When this metalloid enters the body, 
iAs is metabolized from arsenate to arsenite and then metabo-
lized by oxidative methylation to monomethyl arsenic (MMA). 
After the conversion from arsenate to arsenite, at the final 
methylation stage, dimethylarsinic acid (DMA) is produced [5, 
6]. After exposure to arsenic, 40-60% of absorbed arsenic is 
eliminated by urine. Biological monitoring of arsenic exposure 
has been carried out for many years based on the determina-
tion of methylated metabolites, DMA and MMA, in urine [6].
This toxic metalloid is associated with an increased risk of 
complications, including cardiovascular consequences. Arse-
nic exposure is also related to the diagnosis of metabolic syn-
drome [7,8]. Metabolic syndrome is associated with a number 
of risk factors including abdominal obesity, hypertension, 
high triglycerides, and low high-density lipoprotien (HDL) 
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Evidence suggests that the relationship between arsenic metabolism and diseases, including metabolic syndrome, is complex. The aim 
of this study was to evaluate the different types of arsenic methylation and its association with metabolic syndrome in an arsenic 
endemic area. A cross-sectional study was conducted on 132 subjects from Shahid-Abad Village, Qazvin province, Iran (arsenic 
endemic area). Demographic characteristics, metabolic syndrome, and urinary arsenic species, including  iAs (inorganic arsenic), 
MMA (monomethylarsonic acid), and DMA (dimethylarsinic acid) were measured for all patients and their relationship was analyzed 
by appropriate statistical methods. In this study, 34.5% of the participants had metabolic syndrome. The decrease in %MMA, 
increase in %DMA and increase in secondary methylation index (DMA/MMA) were associated with increased risk of metabolic 
syndrome (p<0.05). We did not find any association between the incidence of metabolic syndrome with primary methylation index 
(MMA/iAs) and %iAs (p>0.05). This study showed that the prevalence of metabolic syndrome was significantly higher in people with 
metabolic syndrome than in the general population. A closer examination revealed that the secondary methylation index is related to 
the metabolic syndrome and its components. Given the higher prevalence of cardiovascular disease and diabetes in patients with 
metabolic syndrome, it is necessary to change the pathogenesis of the disease using comprehensive management methods for 
decreasing patient complications. 
Keywords: arsenic toxicity, metabolism, diabetes, glucose, metabolic syndrome
Received: December 7, 2019 Accepted: May 6, 2020
Corresponding author: Amir Mohammad Kazemifar
Associate Professor in Clinical Toxicology, Department of Clinical Toxicology, Faculty 
of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
E-mail: amir. Kazemifar@yahoo.com
This article is available from: https://eaht.org/
Volume: 35(2), Article ID: e2020006, 6 pages
https://doi.org/10.5620/eaht.e2020006
EAHT
Environmental Analysis Health and Toxicology
